Kee Kiat Yeo, MD
Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Image
Kee Kiat Yeo, MD
Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
Jefferson Medical College of Thomas Jefferson University
2011
Philadelphia
PA
Residency
Pediatrics
Children's National Medical Center
2014
Washington
DC
Fellowship
Pediatric Hematology/Oncology
Children's Hospital Los Angele
2017
Los Angeles
CA
Fellowship
Pediatric Neuro-Oncology
Children's Hospital Los Angeles
2018
Los Angeles
CA
Certifications
American Board of Pediatrics (General)
American Board of Pediatrics (Hematology-Oncology)
Professional History
Dr. Yeo earned his medical degree at Jefferson Medical College of Thomas Jefferson University in 2011. After internship and residency training at Children's National Medical Center, he completed a pediatric Hematology/Oncology and a pediatric neuro-oncology fellowship at Children's Hospital Los Angeles. He was subsequently recruited to join the Dana-Farber/Boston Children's Cancer and Blood Disorders Center as an attending physician and clinician-researcher.
His interests are in the development and conduct of early phase clinical trials, the care of adolescent and young adult (AYA) with primary CNS tumors, and medical education. Dr. Yeo currently leads the AYA neuro-oncology program and the pediatric neuro-oncology fellowship program.
Publications
An Emerging Pediatric CNS Tumor: Imaging Evaluation of H3K27M and BRAF V600E Comutated Midline Tumors. View Abstract
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. View Abstract
Incidental Diffuse Midline Glioma, H3 K27-Altered of the Pons Without Significant Coalterations. View Abstract
Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure. View Abstract
Treatment Approach for Metastatic Intracranial Germinoma: A Multi-Institutional Experience. View Abstract
The association between postoperative photon radiotherapy dose and disease control and salvage treatment in pediatric and adolescent ependymoma: a multi-institutional investigation. View Abstract
Intracranial germ cell tumors: advancement in genomic diagnostics and the need for novel therapeutics. View Abstract
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions. View Abstract
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients. View Abstract
Clinical utility of DNA methylation profiling for choroid plexus tumors. View Abstract
Pediatric-type low-grade gliomas in adolescents and young adults-challenges and emerging paradigms. View Abstract
Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. View Abstract
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial. View Abstract
H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications. View Abstract
Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. View Abstract
Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment. View Abstract
Primary central nervous system germ cell tumors in children and young adults: A review of controversies in diagnostic and treatment approach. View Abstract
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. View Abstract
CNS non-germinomatous germ cell tumor (NGGCT): Lessons from the recent past. View Abstract
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. View Abstract
PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors. View Abstract
DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. View Abstract
Clinical Trial Enrollment Among Adolescent and Young Adults with Primary Central Nervous System Tumors Treated at the Dana-Farber Cancer Institute. View Abstract
The epidemiology of primary and metastatic brain tumors in infancy through childhood. View Abstract
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. View Abstract
Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. View Abstract
Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance. View Abstract
IDH-mutant gliomas with additional class-defining molecular events. View Abstract
Adolescent and young adult neuro-oncology: a comprehensive review. View Abstract
Outcomes after first relapse of childhood intracranial ependymoma. View Abstract
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. View Abstract
Response to Letter by Walker et al. View Abstract
Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. View Abstract
Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. View Abstract
Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. View Abstract
Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. View Abstract
Increasing value of autopsies in patients with brain tumors in the molecular era. View Abstract
Clinical and neuropsychological outcome of pediatric non-midline central nervous system germinoma treated with chemotherapy and reduced dose/volume irradiation: The Children's Hospital Los Angeles experience. View Abstract
Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. View Abstract
Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution. View Abstract
HIV, Cytomegalovirus, and Malaria Infections during Pregnancy Lead to Inflammation and Shifts in Memory B Cell Subsets in Kenyan Neonates. View Abstract
A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group. View Abstract
Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. View Abstract
The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report. View Abstract
Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance. View Abstract
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide. View Abstract
Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. View Abstract
Brain Tumors in Children View Abstract